Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
2.
Cent European J Urol ; 73(4): 427-431, 2020.
Article in English | MEDLINE | ID: mdl-33552567

ABSTRACT

INTRODUCTION: Radical cystectomy (RC) is a complex procedure with high perioperative morbidity. In an effort to reduce complications, robotic-assisted RC (RARC) has been adopted as a minimally invasive alternative to the open approach (ORC). Herein, we examine post-operative outcomes of the two surgical approaches in the United States (US) using a large all-payer database. MATERIAL AND METHODS: Using International Classification of Disease, ninth revision (ICD-9) codes, patient who underwent RC were captured from National Inpatient Sample (2008-2014). ICD-9 diagnosis and procedure codes were used to identify post-operative complications. Trends in the utilization of RARC were analyzed. Logistic and log-linear regression accounting for hospital sample weights and sampling years were performed to analyze outcomes after adjustment of pertinent covariates. RESULTS: Of 11,189 patients, 14% underwent RARC. RARC was performed in more teaching hospitals, male patients, those with private insurance, and lower comorbidity score. Performance of RARC steadily increased over the study period (p <0.01). In the last year of the study, 22.8% of cases performed robotically. The weighted average length-of-stay were 10.4 and 8.79 days for ORC and RARC, respectively (p <0.01). In multivariable analyses, RARC was associated with decreased blood transfusion, parenteral nutrition, pneumonia, surgical-site infection, wound and respiratory complications (all, p <0.05). No significant differences were found for in-hospital mortality, cardiac, genitourinary, and vascular complications. CONCLUSIONS: Performance of RARC has significantly increased in recent years. RARC appears safe and feasible for select patients. Earlier discharge and lower complications were noted for those undergoing RARC across different hospital systems nationwide.

4.
Cancer Med ; 8(15): 6780-6788, 2019 11.
Article in English | MEDLINE | ID: mdl-31509346

ABSTRACT

BACKGROUND: Racial/ethnic minority groups have a higher burden of renal cell carcinoma (RCC), but RCC among Hispanic Americans (HAs) and American Indians and Alaska Natives (AIs/ANs) are clinically not well characterized. We explored variations in age at diagnosis and frequencies of RCC histologic subtypes across racial/ethnic groups and Hispanic subgroups using National Cancer Database (NCDB) and Arizona Cancer Registry Data. METHODS: Adult RCC cases with known race/ethnicity were included. Logistic regression analysis was performed to estimate odds and 95% confidence interval (CI) of early-onset (age at diagnosis <50 years) and diagnosis with clear cell RCC (ccRCC) or papillary RCC. RESULTS: A total of 405 073 RCC cases from NCDB and 9751 cases from ACR were identified and included. In both datasets, patients from racial/ethnic minority groups had a younger age at diagnosis than non-Hispanic White (NHW) patients. In the NCDB, AIs/ANs had twofold increased odds (OR, 2.21; 95% CI, 1.88-2.59) of early-onset RCC compared with NHWs. HAs also had twofold increased odds of early-onset RCC (OR, 2.14; 95% CI, 1.79-2.55) in the ACR. In NCDB, ccRCC was more prevalent in AIs (86.3%) and Mexican Americans (83.5%) than NHWs (72.5%). AIs/ANs had twofold increased odds of diagnosis with ccRCC (OR, 2.18; 95% CI, 1.85-2.58) in the NCDB, but the association was stronger in the ACR (OR, 2.83; 95% CI, 2.08-3.85). Similarly, Mexican Americans had significantly increased odds of diagnosis with ccRCC (OR, 2.00; 95% CI, 1.78-2.23) in the NCDB. CONCLUSIONS: This study reports younger age at diagnosis and higher frequencies of ccRCC histologic subtype in AIs/ANs and Hispanic subgroups. These variations across racial/ethnic groups and Hispanic subgroups may have potential clinical implications.


Subject(s)
Carcinoma, Renal Cell/ethnology , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/ethnology , Kidney Neoplasms/pathology , Age Factors , Age of Onset , Aged , Arizona/ethnology , Female , Hispanic or Latino/statistics & numerical data , Humans , Logistic Models , Male , Middle Aged , United States
5.
Curr Opin Urol ; 29(3): 286-292, 2019 05.
Article in English | MEDLINE | ID: mdl-30730389

ABSTRACT

PURPOSE OF REVIEW: Penile cancer is a rare disease with significant physical and psychosocial morbidity. It has a propensity to spread to the inguinal lymph nodes where it can progress to the pelvis and beyond. Here, we present a contemporary review on the surgical management of the lymph nodes. RECENT FINDINGS: Appropriate management of the lymph nodes is critical, and has been shown to impact survival for these patients. Those with lower stage disease can achieve cure with inguinal lymph node dissection (ILND), whereas a multidisciplinary approach is required in those with more extensive disease. Tertiary referral center should be strongly considered. Advances in surgical techniques have allowed for improved outcomes and lower morbidity postoperatively. Modified ILND can be safely performed for those with nonpalpable nodes, whereas diagnostic sentinel node biopsy is a good alternative in centers of experience. Minimally invasive ILND has recently gained popularity with favorable results at short-term follow-up. For those with more advanced disease, the literature remains scarce with no high-level evidence as of yet. SUMMARY: Early upfront surgery appears the best way to approach men with early involvement of the inguinal lymph nodes, whereas systemic therapy is typically reserved for higher volume disease. Clinical trial enrollment continues to be a priority to garner more evidence-based recommendations for this aggressive malignancy.


Subject(s)
Lymph Node Excision/methods , Lymph Nodes/pathology , Lymph Nodes/surgery , Lymphatic Metastasis/therapy , Penile Neoplasms/pathology , Humans , Inguinal Canal , Male , Neoplasm Staging , Penile Neoplasms/surgery , Penile Neoplasms/therapy , Sentinel Lymph Node Biopsy/methods
6.
Clin Genitourin Cancer ; 17(1): e195-e202, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30459061

ABSTRACT

BACKGROUND: Racial/ethnic minority groups, including Hispanic Americans (HAs) and Native Americans (NAs), have a heavier burden of kidney cancer than European Americans (EAs). We investigated variations in clinical characteristics of HA and NA patients with renal cell carcinoma (RCC) who were previously underrepresented. MATERIALS AND METHODS: Clinical records of 294 patients with RCC (151 EAs, 95 HAs, 22 NAs, and 26 others) without prior diagnosis of cancer were reviewed. Logistic regression analysis was performed to understand patients' clinical characteristics. RESULTS: HAs had about 5 years younger average age at diagnosis than EAs (55.8 vs. 60.5 years) and an almost 3-fold increased odds of diagnosis before age 50 years (odds ratio [OR], 2.77; 95% confidence interval [CI], 1.39-5.54). The mean age of diagnosis among NAs was 49.7 years, and NAs had an over 6-fold higher odds of diagnosis at a younger age (OR, 6.23; 95% CI, 2.00-19.46). Clear-cell RCC (ccRCC) was more common in HAs and NAs than EAs. Over 90% of HA patients had ccRCC, whereas only 78.8% of EA patients had ccRCC. HAs had increased odds of diagnosis with ccRCC compared with EAs (OR, 2.79; 95% CI, 1.15-6.80). Among HAs, older patients and patients who spoke Spanish as their primary language were more likely to have advanced stage RCC at diagnosis (OR, 10.48; 95% CI, 1.69-64.89 and OR, 4.61; 95% CI, 1.38-15.40). CONCLUSION: HA and NA patients with RCC had different clinical characteristics than EA patients. It is necessary to better understand the clinical characteristics of these underserved HA and NA populations with high kidney cancer burden.


Subject(s)
Carcinoma, Renal Cell/ethnology , Carcinoma, Renal Cell/pathology , Ethnicity/statistics & numerical data , Kidney Neoplasms/ethnology , Kidney Neoplasms/pathology , Minority Groups/statistics & numerical data , Racial Groups , Aged , Carcinoma, Renal Cell/surgery , Female , Follow-Up Studies , Healthcare Disparities/ethnology , Humans , Kidney Neoplasms/surgery , Male , Middle Aged , Nephrectomy , Prognosis , Retrospective Studies
7.
Can J Urol ; 22(5): 7947-51, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26432963

ABSTRACT

INTRODUCTION: Bladder cancer is the sixth most common cancer in the Western world. Patients with bladder cancer require close monitoring, which may include frequent cystoscopy and urine cytology. Such monitoring results in significant health care cost. The application of epigenetics may allow for a risk adapted approach and more cost-effective method of monitoring. A number of epigenetic changes have been described for many cancer sites, including the urinary bladder. In this review, we discuss the use of epigenetics in bladder cancer and the potential diagnostic and therapeutic applications. MATERIALS AND METHODS: A comprehensive search of the English medical literature was conducted in PubMed using the terms microRNA regulation, DNA methylation, histone modification and bladder cancer. RESULTS: The most important epigenetic changes include DNA methylation, histone modification and microRNA regulation. Both DNA hypomethylation and hypermethylation have been associated with higher rate of cancer. The association of epigenetic changes with bladder cancer has led to the research of its diagnostic and prognostic implications as well as to the development of novel drugs to target these changes with the aim of achieving a survival benefit. CONCLUSIONS: Recently, epigenetics has been shown to play a much greater role than previously anticipated in the initiation and propagation of many tumors. The use of epigenetics for the diagnosis and treatment of bladder cancer is an evolving and promising field. The possibility of reversing epigenetic changes may facilitate additional cancer treatment options in the future.


Subject(s)
DNA Methylation , Epigenomics , Histone Code , MicroRNAs/genetics , Urinary Bladder Neoplasms/diagnosis , Urinary Bladder Neoplasms/genetics , Biomarkers, Tumor/genetics , Epigenesis, Genetic , Histone Deacetylase Inhibitors/therapeutic use , Humans , Methyltransferases/antagonists & inhibitors , Prognosis , Urinary Bladder Neoplasms/drug therapy
8.
Int Marit Health ; 66(1): 28-9, 2015.
Article in English | MEDLINE | ID: mdl-25792164

ABSTRACT

A crew member had a foreign body implanted subcutaneously on his dorsum penis stealthily 6 years earlier by a fellow crew member without any medical training. He presented to the ship's medical centre after a week of pain, erythema and oedema over the foreign body, which was eventually removed by the patient, leaving behind a penile ulceration. He was treated conservatively initially with intravenous and then with oral antibiotics until complete secondary wound closure was achieved.


Subject(s)
Body Modification, Non-Therapeutic/adverse effects , Foreign-Body Reaction/etiology , Penile Diseases/etiology , Ulcer/etiology , Adult , Body Modification, Non-Therapeutic/instrumentation , Foreign-Body Reaction/diagnosis , Foreign-Body Reaction/ethnology , Humans , Male , Naval Medicine , Penile Diseases/diagnosis , Penile Diseases/ethnology , Philippines/ethnology , Ulcer/diagnosis , Ulcer/ethnology
9.
Int Marit Health ; 65(3): 122-3, 2014.
Article in English | MEDLINE | ID: mdl-25471160

ABSTRACT

Spontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndrome that has been associated with peripartum and postpartum periods. It results from the separation of the layers of the arterial wall of the coronary artery with the subsequent formation of a false lumen. We report a case of a 54-year-old female who presented to the cruise ship's medical facility complaining of epigastralgia and dizziness. Work up including an electrocardiography and cardiac profile was ordered. Results yielded a diagnosis of non-ST segment elevation myocardial infarction (NSTEMI). Treatment following American Heart Association recommendations including nitrates, clopidogrel and enoxaparin was given. After debarkation at sea and referral to a reference hospital, the patient was diagnosed with SCAD. Patient's outcome was favorable and she was discharged home a few days after, despite being managed as a NSTEMI.


Subject(s)
Coronary Vessel Anomalies/diagnosis , Myocardial Infarction/diagnosis , Myocardial Infarction/drug therapy , Ships , Vascular Diseases/congenital , Abdominal Pain/etiology , Coronary Vessel Anomalies/complications , Dizziness/etiology , Female , Humans , Middle Aged , Myocardial Infarction/etiology , Naval Medicine , Transportation of Patients , Vascular Diseases/complications , Vascular Diseases/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...